Get intelligentvalue.com

Own it today or select a payment plan

Secured by Stripe

Premium Domain Name

intelligentvalue.com

intelligentvalue.com logo

is available for purchase

51 views
Visitors fromUSUS 54%·AUAU 32%·ININ 7%·GBGB 2%·FRFR 2%

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

VisaMastercardAmerican ExpressDiscoverDiners ClubJCBApple PayGoogle Pay

Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the LD Micro Main Event XV Conference as follows:

Date:Wednesday, October 26, 2022
Time:6:00PM ET
Register to watch the event here:Click Here
  

The webcast will be accessible via the Company’s website at https://ir.etonpharma.com/ in the Investors section under Events and Presentations.

Eton will be participating in 1x1 meetings, which can be requested through your LD Micro representative.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases. The Company currently commercializes ALKINDI SPRINKLE® and Carglumic Acid tablets and has four additional rare disease products under development, including dehydrated alcohol injection and the ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com 

Source: Eton Pharmaceuticals


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  241.70
+3.36 (1.41%)
AAPL  294.38
+5.02 (1.73%)
AMD  540.88
-40.03 (-6.89%)
BAC  58.36
+1.38 (2.42%)
GOOG  357.89
+4.56 (1.29%)
META  612.91
+49.62 (8.81%)
MSFT  384.28
+11.26 (3.02%)
NVDA  197.58
-2.51 (-1.25%)
ORCL  142.50
-4.05 (-2.76%)
TSLA  425.30
+4.70 (1.12%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.